Metabolite and lipoprotein profiles reveal sex-related oxidative stress imbalance in de novo drug-naive Parkinson's disease patients.
Journal
NPJ Parkinson's disease
ISSN: 2373-8057
Titre abrégé: NPJ Parkinsons Dis
Pays: United States
ID NLM: 101675390
Informations de publication
Date de publication:
08 Feb 2022
08 Feb 2022
Historique:
received:
21
04
2021
accepted:
16
12
2021
entrez:
9
2
2022
pubmed:
10
2
2022
medline:
10
2
2022
Statut:
epublish
Résumé
Parkinson's disease (PD) is the neurological disorder showing the greatest rise in prevalence from 1990 to 2016. Despite clinical definition criteria and a tremendous effort to develop objective biomarkers, precise diagnosis of PD is still unavailable at early stage. In recent years, an increasing number of studies have used omic methods to unveil the molecular basis of PD, providing a detailed characterization of potentially pathological alterations in various biological specimens. Metabolomics could provide useful insights to deepen our knowledge of PD aetiopathogenesis, to identify signatures that distinguish groups of patients and uncover responsive biomarkers of PD that may be significant in early detection and in tracking the disease progression and drug treatment efficacy. The present work is the first large metabolomic study based on nuclear magnetic resonance (NMR) with an independent validation cohort aiming at the serum characterization of de novo drug-naive PD patients. Here, NMR is applied to sera from large training and independent validation cohorts of German subjects. Multivariate and univariate approaches are used to infer metabolic differences that characterize the metabolite and the lipoprotein profiles of newly diagnosed de novo drug-naive PD patients also in relation to the biological sex of the subjects in the study, evidencing a more pronounced fingerprint of the pathology in male patients. The presence of a validation cohort allowed us to confirm altered levels of acetone and cholesterol in male PD patients. By comparing the metabolites and lipoproteins levels among de novo drug-naive PD patients, age- and sex-matched healthy controls, and a group of advanced PD patients, we detected several descriptors of stronger oxidative stress.
Identifiants
pubmed: 35136088
doi: 10.1038/s41531-021-00274-8
pii: 10.1038/s41531-021-00274-8
pmc: PMC8826921
doi:
Types de publication
Journal Article
Langues
eng
Pagination
14Subventions
Organisme : EC | Horizon 2020 Framework Programme (EU Framework Programme for Research and Innovation H2020)
ID : 634821
Organisme : EC | EU Framework Programme for Research and Innovation H2020 | H2020 Priority Societal Challenges | H2020 Health (H2020 Societal Challenges - Health, Demographic Change and Well-being)
ID : 634821
Investigateurs
Alessandra Dal Molin
(AD)
Anna Bartoletti-Stella
(A)
Anna Gabellini
(A)
Astrid Daniela Adarmes-Gómez
(AD)
Cesa Lorella Maria Scaglione
(CLM)
Christine Nardini
(C)
Cilea Rosaria
(C)
Claudia Boninsegna
(C)
Claudia Sala
(C)
Cristina Giuliani
(C)
Cristina Tejera-Parrado
(C)
Daniel Macias
(D)
Dolores Buiza-Rueda
(D)
Dylan Williams
(D)
Elisa Zago
(E)
Federica Provini
(F)
Francesca Magrinelli
(F)
Francesco Mignani
(F)
Francesco Ravaioli
(F)
Franco Valzania
(F)
Friederike Sixel-Döring
(F)
Giacomo Mengozzi
(G)
Giovanna Calandra-Buonaura
(G)
Giovanna Maria Dimitri
(GM)
Giovanni Fabbri
(G)
Henry Houlden
(H)
Ismael Huertas
(I)
Ivan Doykov
(I)
Jenny Hällqvist
(J)
Juan Francisco Martín Rodríguez
(JFM)
Juulia Jylhävä
(J)
Kailash P Bhatia
(KP)
Kevin Mills
(K)
Luca Baldelli
(L)
Luciano Xumerle
(L)
Luisa Sambati
(L)
Maddalena Milazzo
(M)
Marcella Broli
(M)
Maria Giovanna Maturo
(MG)
Maria Teresa Periñán-Tocino
(MT)
Mario Carriòn-Claro
(M)
Marta Bonilla-Toribio
(M)
Massimo Delledonne
(M)
Miguel A Labrador-Espinosa
(MA)
Nancy L Pedersen
(NL)
Pablo Mir
(P)
Patrizia De Massis
(P)
Pietro Cortelli
(P)
Pietro Guaraldi
(P)
Pietro Liò
(P)
Pilar Gómez-Garre
(P)
Robert Clayton
(R)
Rocio Escuela-Martin
(R)
Rosario Vigo Ortega
(RV)
Sabina Capellari
(S)
Sara Hägg
(S)
Sebastian R Schreglmann
(SR)
Silvia De Luca
(S)
Simeon Spasov
(S)
Stefania Alessandra Nassetti
(SA)
Stefania Macrì
(S)
Tiago Azevedo
(T)
Wendy Heywood
(W)
Informations de copyright
© 2022. The Author(s).
Références
Tysnes, O.-B. & Storstein, A. Epidemiology of Parkinson’s disease. J. Neural Transm. Vienna Austria 1996(124), 901–905 (2017).
doi: 10.1007/s00702-017-1686-y
Agarwal, P. A. & Stoessl, A. J. Biomarkers for trials of neuroprotection in Parkinson’s disease. Mov. Disord. J. Mov. Disord. Soc. 28, 71–85 (2013).
doi: 10.1002/mds.25065
Trezzi, J.-P. et al. Distinct metabolomic signature in cerebrospinal fluid in early Parkinson’s disease. Mov. Disord. J. Mov. Disord. Soc. 32, 1401–1408 (2017).
doi: 10.1002/mds.27132
Chang, K.-H. et al. Alternations of metabolic profile and kynurenine metabolism in the plasma of Parkinson’s disease. Mol. Neurobiol. 55, 6319–6328 (2018).
pubmed: 29294246
doi: 10.1007/s12035-017-0845-3
Phelan, M. M., Caamaño-Gutiérrez, E., Gant, M. S., Grosman, R. X. & Madine, J. Using an NMR metabolomics approach to investigate the pathogenicity of amyloid-beta and alpha-synuclein. Metabolomics 13, 151 (2017).
pubmed: 29142509
pmcid: 5661010
doi: 10.1007/s11306-017-1289-5
Hatano, T., Saiki, S., Okuzumi, A., Mohney, R. P. & Hattori, N. Identification of novel biomarkers for Parkinson’s disease by metabolomic technologies. J. Neurol. Neurosurg. Psychiatry 87, 295–301 (2016).
pubmed: 25795009
doi: 10.1136/jnnp-2014-309676
Emamzadeh, F. N. & Surguchov, A. Parkinson’s disease: biomarkers, treatment, and risk factors. Front. Neurosci. 12, 612 (2018).
pubmed: 30214392
pmcid: 6125353
doi: 10.3389/fnins.2018.00612
Nagesh Babu, G. et al. Serum metabolomics study in a group of Parkinson’s disease patients from northern India. Clin. Chim. Acta Int. J. Clin. Chem. 480, 214–219 (2018).
doi: 10.1016/j.cca.2018.02.022
Shao, Y. & Le, W. Recent advances and perspectives of metabolomics-based investigations in Parkinson’s disease. Mol. Neurodegener. 14, 3 (2019).
pubmed: 30634989
pmcid: 6330496
doi: 10.1186/s13024-018-0304-2
Lei, S. & Powers, R. NMR metabolomics analysis of Parkinson’s disease. Curr. Metabolomics 1, 191–209 (2013).
pubmed: 26078917
pmcid: 4465192
doi: 10.2174/2213235X113019990004
Troisi, J. et al. A metabolomic signature of treated and drug-naïve patients with Parkinson’s disease: a pilot study. Metabolomics 15, 90 (2019).
pubmed: 31183578
doi: 10.1007/s11306-019-1554-x
Takis, P. G., Ghini, V., Tenori, L., Turano, P. & Luchinat, C. Uniqueness of the NMR approach to metabolomics. TrAC Trends Anal. Chem. 120, 115300 (2019).
doi: 10.1016/j.trac.2018.10.036
Dani, C. et al. Metabolomic profile of term infants of gestational diabetic mothers. J. Matern. Fetal Neonatal Med. 27, 537–542 (2014).
pubmed: 23844701
doi: 10.3109/14767058.2013.823941
Meoni, G. et al. The metabolic fingerprints of HCV and HBV infections studied by Nuclear Magnetic Resonance Spectroscopy. Sci. Rep. 9, 4128 (2019).
pubmed: 30858406
pmcid: 6412048
doi: 10.1038/s41598-019-40028-4
Vignoli, A. et al. Metabolic signature of primary biliary cholangitis and its comparison with celiac disease. J. Proteome Res. 18, 1228–1236 (2019).
pubmed: 30539636
doi: 10.1021/acs.jproteome.8b00849
Vignoli, A. et al. Fingerprinting Alzheimer’s disease by 1H nuclear magnetic resonance spectroscopy of cerebrospinal fluid. J. Proteome Res. 19, 1696–1705 (2020).
pubmed: 32118444
doi: 10.1021/acs.jproteome.9b00850
Caracausi, M. et al. Plasma and urinary metabolomic profiles of Down syndrome correlate with alteration of mitochondrial metabolism. Sci. Rep. 8, 2977 (2018).
pubmed: 29445163
pmcid: 5813015
doi: 10.1038/s41598-018-20834-y
Ghini, V. et al. Metabolomics profiling of pre-and post-anesthesia plasma samples of colorectal patients obtained via Ficoll separation. Metabolomics 11, 1769–1778 (2015).
pubmed: 26491424
pmcid: 4605980
doi: 10.1007/s11306-015-0832-5
Romano, F. et al. Effect of non-surgical periodontal therapy on salivary metabolic fingerprint of generalized chronic periodontitis using nuclear magnetic resonance spectroscopy. Arch. Oral. Biol. 97, 208–214 (2018).
pubmed: 30396039
doi: 10.1016/j.archoralbio.2018.10.023
Citterio, F. et al. Changes in the salivary metabolic profile of generalized periodontitis patients after non-surgical periodontal therapy: a metabolomic analysis using nuclear magnetic resonance spectroscopy. J. Clin. Med. 9, 3977 (2020).
pmcid: 7763572
doi: 10.3390/jcm9123977
Vignoli, A. et al. NMR-based metabolomics identifies patients at high risk of death within two years after acute myocardial infarction in the AMI-Florence II cohort. BMC Med. 17, 3 (2019).
pubmed: 30616610
pmcid: 6323789
doi: 10.1186/s12916-018-1240-2
Di Donato, S. et al. Serum metabolomic as biomarkers to differentiate early from metastatic disease in elderly colorectal cancer (crc) patients. Ann. Oncol. 27, 2762 (2016).
doi: 10.1093/annonc/mdw335.20
Meoni, G. et al. Metabolomic/lipidomic profiling of COVID-19 and individual response to tocilizumab. PLOS Pathog. 17, e1009243 (2021).
pubmed: 33524041
pmcid: 7877736
doi: 10.1371/journal.ppat.1009243
D’Andrea, G. et al. Different circulating trace amine profiles in de novo and treated Parkinson’s disease patients. Sci. Rep. 9, 6151 (2019).
pubmed: 30992490
pmcid: 6467876
doi: 10.1038/s41598-019-42535-w
Shao, Y. et al. Comprehensive metabolic profiling of Parkinson’s disease by liquid chromatography-mass spectrometry. Mol. Neurodegener. 16, 4 (2021).
pubmed: 33485385
pmcid: 7825156
doi: 10.1186/s13024-021-00425-8
Trupp, M. et al. Metabolite and peptide levels in plasma and CSF differentiating healthy controls from patients with newly diagnosed Parkinson’s disease. J. Park. Dis. 4, 549–560 (2014).
Pirazzini, C. et al. A geroscience approach for Parkinson’s disease: conceptual framework and design of PROPAG-AGEING project. Mech. Ageing Dev. 194, 111426 (2021).
pubmed: 33385396
doi: 10.1016/j.mad.2020.111426
Vignoli, A. et al. High-throughput metabolomics by 1D NMR. Angew. Chem. Int. Ed. Engl. 58, 968–994 (2019).
pubmed: 29999221
doi: 10.1002/anie.201804736
Vignoli, A., Tenori, L., Luchinat, C. & Saccenti, E. Age and sex effects on plasma metabolite association networks in healthy subjects. J. Proteome Res. 17, 97–107 (2018).
pubmed: 29090929
doi: 10.1021/acs.jproteome.7b00404
Wallner-Liebmann, S. et al. The impact of free or standardized lifestyle and urine sampling protocol on metabolome recognition accuracy. Genes Nutr. 10, 441 (2015).
pubmed: 25403096
doi: 10.1007/s12263-014-0441-3
Wallner-Liebmann, S. et al. Individual human metabolic phenotype analyzed by (1)H NMR of saliva samples. J. Proteome Res. 15, 1787–1793 (2016).
pubmed: 27087681
doi: 10.1021/acs.jproteome.5b01060
Assfalg, M. et al. Evidence of different metabolic phenotypes in humans. Proc. Natl Acad. Sci. USA 105, 1420–1424 (2008).
pubmed: 18230739
pmcid: 2234159
doi: 10.1073/pnas.0705685105
Bernini, P. et al. Individual human phenotypes in metabolic space and time. J. Proteome Res. 8, 4264–4271 (2009).
pubmed: 19527021
doi: 10.1021/pr900344m
Ghini, V., Saccenti, E., Tenori, L., Assfalg, M. & Luchinat, C. Allostasis and resilience of the human individual metabolic phenotype. J. Proteome Res. 14, 2951–2962 (2015).
pubmed: 26055080
doi: 10.1021/acs.jproteome.5b00275
Cerri, S., Mus, L. & Blandini, F. Parkinson’s disease in women and men: what’s the difference? J. Park. Dis. 9, 501–515 (2019).
Baldereschi, M. et al. Parkinson’s disease and parkinsonism in a longitudinal study: two-fold higher incidence in men. ILSA Working Group. Italian Longitudinal Study on Aging. Neurology 55, 1358–1363 (2000).
pubmed: 11087781
doi: 10.1212/WNL.55.9.1358
McPherson, P. A. C. & McEneny, J. The biochemistry of ketogenesis and its role in weight management, neurological disease and oxidative stress. J. Physiol. Biochem. 68, 141–151 (2012).
pubmed: 21983804
doi: 10.1007/s13105-011-0112-4
Jimenez-Moreno, N. & Lane, J. D. Autophagy and redox homeostasis in Parkinson’s: a crucial balancing act. Oxid. Med. Cell. Longev. 2020, e8865611 (2020).
doi: 10.1155/2020/8865611
Straub, J. M. & Hausdörfer, J. Accumlation of acetone in blood during long-term anaesthesia with closed systems. Br. J. Anaesth. 70, 363–364 (1993).
doi: 10.1093/bja/70.3.363
Cocco, E. et al. 1H-NMR analysis provides a metabolomic profile of patients with multiple sclerosis. Neurol. Neuroimmunol. Neuroinflammation 3, e185 (2015).
Kumar, A. et al. Metabolomic analysis of serum by (1) H NMR spectroscopy in amyotrophic lateral sclerosis. Clin. Chim. Acta Int. J. Clin. Chem. 411, 563–567 (2010).
doi: 10.1016/j.cca.2010.01.016
Paul, V. N., Chopra, K. & Kulkarni, S. K. Prooxidant role of histidine in hypoxic stressed mice and Fe(3+)-induced lipid peroxidation. Methods Find. Exp. Clin. Pharmacol. 22, 551–555 (2000).
pubmed: 11196342
Kumari, S. et al. Quantitative metabolomics of saliva using proton NMR spectroscopy in patients with Parkinson’s disease and healthy controls. Neurol. Sci. 41, 1201–1210 (2020).
pubmed: 31897951
doi: 10.1007/s10072-019-04143-4
Figura, M. et al. Serum amino acid profile in patients with Parkinson’s disease. PLoS ONE 13, e0191670 (2018).
pubmed: 29377959
pmcid: 5788376
doi: 10.1371/journal.pone.0191670
Abdel-Salam, O. M. E. et al. Citric acid effects on brain and liver oxidative stress in lipopolysaccharide-treated mice. J. Med. Food 17, 588–598 (2014).
pubmed: 24433072
pmcid: 4026104
doi: 10.1089/jmf.2013.0065
Takahashi, T. et al. N, N-Dimethylglycine decreases oxidative stress and improves in vitro development of bovine embryos. J. Reprod. Dev. 62, 209–212 (2016).
pubmed: 26875568
pmcid: 4848579
doi: 10.1262/jrd.2015-149
Campbell, K., Vowinckel, J., Keller, M. A. & Ralser, M. Methionine metabolism alters oxidative stress resistance via the pentose phosphate pathway. Antioxid. Redox Signal. 24, 543–547 (2016).
pubmed: 26596469
pmcid: 4827311
doi: 10.1089/ars.2015.6516
Quijano, C., Trujillo, M., Castro, L. & Trostchansky, A. Interplay between oxidant species and energy metabolism. Redox Biol. 8, 28–42 (2015).
pubmed: 26741399
pmcid: 4710798
doi: 10.1016/j.redox.2015.11.010
Postuma, R. B. & Lang, A. E. Homocysteine and levodopa: should Parkinson disease patients receive preventative therapy? Neurology 63, 886–891 (2004).
pubmed: 15365141
doi: 10.1212/01.WNL.0000137886.74175.5A
Rozycka, A., Jagodzinski, P. P., Kozubski, W., Lianeri, M. & Dorszewska, J. Homocysteine level and mechanisms of injury in Parkinson’s disease as related to MTHFR, MTR, and MTHFD1 genes polymorphisms and L-dopa treatment. Curr. Genomics 14, 534–542 (2013).
pubmed: 24532985
pmcid: 3924248
doi: 10.2174/1389202914666131210210559
Pizarro, C., Esteban-Díez, I., Espinosa, M., Rodríguez-Royo, F. & González-Sáiz, J.-M. An NMR-based lipidomic approach to identify Parkinson’s disease-stage specific lipoprotein–lipid signatures in plasma. Analyst 144, 1334–1344 (2019).
pubmed: 30564825
doi: 10.1039/C8AN01778F
Zhang, L. et al. Circulating cholesterol levels may link to the factors influencing Parkinson’s risk. Front. Neurol. 8, 501 (2017).
pubmed: 29021777
pmcid: 5624032
doi: 10.3389/fneur.2017.00501
Huang, X. et al. Lower low density lipid cholesterol levels are associated with Parkinson’s disease. Mov. Disord. J. Mov. Disord. Soc. 22, 377–381 (2007).
doi: 10.1002/mds.21290
Lau, D., L, L. M., Koudstaal, P. J., Hofman, A. & Breteler, M. M. B. Serum cholesterol levels and the risk of Parkinson’s disease. Am. J. Epidemiol. 164, 998–1002 (2006).
pubmed: 16905642
doi: 10.1093/aje/kwj283
Gudala, K., Bansal, D. & Muthyala, H. Role of serum cholesterol in Parkinson’s disease: a meta-analysis of evidence. J. Park. Dis. 3, 363–370 (2013).
Hu, L. et al. Integrated metabolomics and proteomics analysis reveals plasma lipid metabolic disturbance in patients with Parkinson’s disease. Front. Mol. Neurosci. 13, 80 (2020).
Xicoy, H., Wieringa, B. & Martens, G. J. M. The role of lipids in Parkinson’s disease. Cells 8, 27 (2019).
Hu, G. Total cholesterol and the risk of Parkinson’s disease: a review for some new findings. Park. Dis. 2010, 836962 (2010).
Mollenhauer, B. et al. Nonmotor and diagnostic findings in subjects with de novo Parkinson disease of the DeNoPa cohort. Neurology 81, 1226–1234 (2013).
pubmed: 23997153
doi: 10.1212/WNL.0b013e3182a6cbd5
Rozani, V. et al. Higher serum cholesterol and decreased Parkinson’s disease risk: a statin-free cohort study. Mov. Disord. 33, 1298–1305 (2018).
pubmed: 30145829
doi: 10.1002/mds.27413
Huang, X., Abbott, R. D., Petrovitch, H., Mailman, R. B. & Ross, G. W. Low LDL cholesterol and increased risk of Parkinson’s disease: prospective results from Honolulu-Asia Aging Study. Mov. Disord. 23, 1013–1018 (2008).
pubmed: 18381649
doi: 10.1002/mds.22013
Mollenhauer, B. et al. Monitoring of 30 marker candidates in early Parkinson disease as progression markers. Neurology 87, 168–177 (2016).
pubmed: 27164658
pmcid: 4940068
doi: 10.1212/WNL.0000000000002651
Sixel-Döring, F., Zimmermann, J., Wegener, A., Mollenhauer, B. & Trenkwalder, C. The evolution of REM sleep behavior disorder in early Parkinson disease. Sleep 39, 1737–1742 (2016).
pubmed: 27306265
pmcid: 4989262
doi: 10.5665/sleep.6102
Schade, S. et al. Acute levodopa challenge test in patients with de novo Parkinson’s disease: data from the DeNoPa cohort. Mov. Disord. Clin. Pract. 4, 755–762 (2017).
pubmed: 30363372
pmcid: 6174366
doi: 10.1002/mdc3.12511
Clarke, C. E. et al. Clinical effectiveness and cost-effectiveness of physiotherapy and occupational therapy versus no therapy in mild to moderate Parkinson’s disease: a large pragmatic randomised controlled trial (PD REHAB). Health Technol. Assess. Winch. Engl. 20, 1–96 (2016).
doi: 10.3310/hta20630
Wenning, G. K., Tison, F., Ben Shlomo, Y., Daniel, S. E. & Quinn, N. P. Multiple system atrophy: a review of 203 pathologically proven cases. Mov. Disord. 12, 133–147 (1997).
pubmed: 9087971
doi: 10.1002/mds.870120203
McKeith, I. Dementia with Lewy bodies. Dialogues Clin. Neurosci. 6, 333–341 (2004).
pubmed: 22033743
pmcid: 3181810
doi: 10.31887/DCNS.2004.6.3/imckeith
Collins, S. J., Ahlskog, J. E., Parisi, J. E. & Maraganore, D. M. Progressive supranuclear palsy: neuropathologically based diagnostic clinical criteria. J. Neurol. Neurosurg. Psychiatry 58, 167–173 (1995).
pubmed: 7876846
pmcid: 1073312
doi: 10.1136/jnnp.58.2.167
Reich, S. G. & Grill, S. E. Corticobasal degeneration. Curr. Treat. Options Neurol. 11, 179–185 (2009).
pubmed: 19364452
doi: 10.1007/s11940-009-0021-9
Warren, J. D., Rohrer, J. D. & Rossor, M. N. Frontotemporal dementia. BMJ 347, f4827 (2013).
ISO/DIS 23118 Molecular in vitro diagnostic examinations—specifications for pre-examination processes in metabolomics in urine, venous blood serum and plasma. ISO, https://www.iso.org/obp/ui/#iso:std:iso:23118:ed-1:v1:en (2021).
Bernini, P. et al. Standard operating procedures for pre-analytical handling of blood and urine for metabolomic studies and biobanks. J. Biomol. NMR 49, 231–243 (2011).
pubmed: 21380509
doi: 10.1007/s10858-011-9489-1
Ghini, V., Quaglio, D., Luchinat, C. & Turano, P. NMR for sample quality assessment in metabolomics. N. Biotechnol. 52, 25–34 (2019).
pubmed: 31022482
doi: 10.1016/j.nbt.2019.04.004
Lipoprotein Subclass Analysis Enabling Tools on the IVDr Platform. Bruker.com https://www.bruker.com/products/mr/nmr-preclinical-screening/lipoprotein-subclass-analysis.html .
Ihaka, R. & Gentleman, R. R: a language for data analysis and graphics. J. Comput Stat. Graph 5, 299–314 (1996).
Serneels, S. & Verdonck, T. Principal component analysis for data containing outliers and missing elements. Comput. Stat. Data Anal. 52, 1712–1727 (2008).
doi: 10.1016/j.csda.2007.05.024
Ebbels, T. M. D. in The Handbook of Metabonomics and Metabolomics 201–226 (Elsevier Science B.V., 2007).
Szymańska, E., Saccenti, E., Smilde, A. K. & Westerhuis, J. A. Double-check: validation of diagnostic statistics for PLS-DA models in metabolomics studies. Metabolomics 8, 3–16 (2012).
pubmed: 22593721
doi: 10.1007/s11306-011-0330-3
Neuhäuser, M. in International Encyclopedia of Statistical Science 1656–1658 (Springer, 2011).
Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. Ser. B Methodol. 57, 289–300 (1995).
Cliff, N. Ordinal Methods for Behavioral Data Analysis (Psychology Press, 1996).
Romano, J., Kromrey, J., Coraggio, J. & Skowronek, J. Appropriate statistics for ordinal level data: should we really be using t-test and Cohen’sd for evaluating group differences on the NSSE and other surveys? In: Annual meeting of the Florida Association of Institutional Research, BibSonomy (2006).
Gelman, A. Scaling regression inputs by dividing by two standard deviations. Stat. Med. 27, 2865–2873 (2008).
pubmed: 17960576
doi: 10.1002/sim.3107